In the absence of data for patients with type 1 SMA and three copies of the SMN2 gene, the company assumed that the efficacy of onasemnogene abeparvovec for these patients was the same as for patients with type 1 SMA and two copies of the SMN2 gene. The gene discussed is SMN2; the disease is spinal muscular atrophy, type 1.